Evaluating the PRASE intervention: a multi-centre, cluster, wait list design, randomised controlled trial with a qualitative process evaluation
Project Lead: Laura Sheard (email@example.com)
Objective: To assess the efficacy of the PRASE patient safety intervention in achieving patient safety improvements over a 12 month period.
Trial: A multi-centre, cluster, wait list randomised controlled trial of a patient safety intervention with a qualitative process evaluation. The trial methods consists of three stages:
Over a 2-3 week period, 25 patients per ward complete the 48 item PMOS questionnaire, and report any safety concerns (or specific positive experiences of care) using the PIRT incident reporting tool. Patients will be given a choice of whether they would prefer to self-complete the questionnaire or have it facilitated by the researcher. There are three measurement periods – at baseline, 6 months and 12 months.
Information for each ward is collated and presented to the ward in the form of a ‘Feedback Report’. PMOS questionnaire scores are shown graphically using a traffic light system to allow staff to see easily which areas they are performing in well, and those areas perhaps in need of improvement.
iii) Action planning and change
Ward staff form an Action Planning Team and identify areas to target for improvement based on patient feedback detailed in the report. The APT is facilitated by a PRASE researcher. Nominated people within the APT takes responsibility for delivering the action plan.
The key elements of the process evaluation are:
- Analysis of documented action plans
- In depth ethnographic observation of the APM
- Structured interviews with key members of the APM
- Detailed fieldworker diaries
Patient recruitment and on-going engagement for the current projects
Three Trusts are taking part in this study: Harrogate & District NHS Foundation Trust, Calderdale & Huddersfield NHS Foundation Trust and Leeds Teaching Hospitals NHS Trust. At the end of the first phase of data collection, 800 participants were recruited in total. It is projected that 800 participants will also be recruited in each of the two remaining data collection phases meaning the overall total for the trial will be 2400 patients.